Beauty Tech Funding: What It Is and Why It Is Surging
Beauty tech funding is the flow of venture and private equity capital into companies that use technology to improve how beauty products and services are developed, delivered and experienced by consumers across both professional and retail channels. The latest deals show investors moving beyond classic cosmetics into automation, data-driven formulations and clinical-grade treatments. On one side are startups building robotic manicure technology that can standardise services inside retail and wellness locations. On the other are large funds backing clinical skincare acquisition strategies that bring doctor-dispensed brands and medical devices under the same umbrella. Together, these moves signal that investors see long-term demand for beauty startup investment that promises more consistent results, better access to professional-quality care and clearer pathways to link at-home beauty with medical aesthetics.
10Beauty and the Rise of Robotic Manicure Technology
10Beauty’s latest funding round highlights why automation is becoming a key theme in beauty tech funding. The company has raised USD 23.5 million (approx. RM108.1 million) in a Series round led by Story Ventures, taking its total funding to USD 70 million (approx. RM322.0 million). 10Beauty operates full-service, autonomous robotic manicure machines that deliver a complete five-step manicure through a pod-based system including polish-removal sponges, cuticle serum, brushes, colour and top coat. The startup already runs in Ulta Beauty stores in Boston and plans to expand into Chicago, with agreements in place for the rollout of its first 850 machines, including Nordstrom and Ulta Beauty partnerships. For consumers, this points to more accessible, standardised nail services in everyday retail environments, shorter wait times and potentially lower prices compared to traditional salons, while retailers gain a new in-store experience without hiring extra technicians.
Bridgepoint’s Obagi Deal and the New Clinical Skincare Playbook
On the clinical side, Bridgepoint Group’s agreement to acquire Obagi Medical from Waldencast for USD 460 million (approx. RM2,116.0 million) shows how beauty startup investment is expanding into doctor-backed brands. The deal follows Bridgepoint’s purchase of Laboratoires Vivacy in 2023 and dermatologist-backed line Roc a year later, building a portfolio that links dermal fillers, medical devices and clinical skincare. According to The Business of Beauty, 25 percent of Obagi’s business must be prescribed by a doctor, while the rest is sold in clinics or via e-commerce. This creates a bridge between consumer beauty aisles and pharmaceutical-grade care, especially as more people look for non-surgical tweakments alongside skincare routines. For consumers, increased consolidation can mean wider access to professional-grade regimens and clearer treatment pathways, though it may also concentrate power among fewer, larger owners.
Consolidation, Confidence and What It Means for Consumers
Taken together, robotic manicure technology and clinical skincare acquisition deals point to a broad thesis: investors believe tech-enabled beauty can scale reliably across retail, professional and medical settings. Beauty tech funding now spans automation, clinical innovation and retail expansion, attracting early-stage venture capital and large private equity alike. Bridgepoint’s head of healthcare described physician-dispensed skincare as one of the fastest-growing segments of the dermatology and aesthetics market, reflecting this confidence. For consumers, the upside includes more predictable outcomes, easier access to professional-level services and integrated journeys from in-store experiences to doctor-led treatments. The risk is that consolidation could reduce niche alternatives or push brands toward growth at the expense of individualised care. The next wave of beauty tech winners will likely be those that balance standardisation and scale with genuine choice, transparency and medical guidance.
